Direct to Angio Suite (DTAS) Philips' CBCT triage
DeviceStroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
NCT Number: NCT04701684
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
La Sagrada Familia Clinic, José Hernández, Argentina
Outcomes for stroke patients are closely tied to how fast they receive treatment. Currently, when a possible stroke patient arrives at the emergency department, typically first a CT or MRI exam is acquired for stroke triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
In the DTAS workflow stroke patients are diagnosed and treated in the interventional suite without interruption. The Cone-Beam CT (CBCT) capabilities of the interventional X-ray system are utilized to perform triage, directly followed by stroke treatment.
The primary objective of the WE-TRUST study is to demonstrate that the DTAS triage workflow involving CBCT results in superior patient outcome in ischemic stroke patients with confirmed Large Vessel Occlusion as compared to the conventional CT/MR triage workflow.
The WE-TRUST study will be running in 16+ sites to enroll 500+ patients globally.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clinical exclusion criteria:
Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
Time frame: 90 ± 14 days follow-up
The difference in the distribution of ordinal modified Rankin Scale (mRS) scores at 90 ± 14 days follow-up in the Target population to determine the performance of the DTAS triage imaging workflow involving Stroke CBCT reconstructions by the investigational device or SmartCT R3 in comparison to the conventional CT/MR triage imaging workflow. The 90 day mRS score will be evaluated by a blinded assessor of a pool of blinded assessors (i.e., a specialist with mRS certification) at the local hospital by performing a structured interview of the patient in person using the Rankin Focused Assessment (RFA) structured mRS questionnaire. If the subject is unable to return to the clinic for the day 90 ± 14 visit, a (video) call in which the mRS score is assessed by a blinded assessor is preferable to no assessment.
Time frame: Peri-procedural time
Door-to-arterial puncture time: Time patient arrives at the Comprehensive Stroke Center door to the time the skin of the patient is touched to perform first arterial puncture.
Time frame: Peri-procedural time
Door-to-reperfusion time: Time patient arrives at the Comprehensive Stroke Center door to the time of successful vessel recanalization (eTICI ≥ 2b)
Time frame: 90 ± 14 days follow-up
The distribution of ordinal modified Rankin Scale (mRS) scores at 90 ± 14 days follow-up in both arms in the Randomized population.
Time frame: At 90 days post-procedure
Mortality and stroke-related mortality
Time frame: At 24 (-12/+24) hours
All intracranial hemorrhages will be classified by the blinded Core Lab using the Heidelberg Bleeding Classification. Symptomatic ICH will be defined as per a modified SITS-MOST definition [31]: Symptomatic intracranial hemorrhage is defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage on the 24 (-12/+24) hours post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 (-12/+24) hours after randomization, or leading to death.
Time frame: At 24 (-12/+24) hours
All intracranial hemorrhages will be classified (blinded) by using the Heidelberg Bleeding Classification. All the intracranial hemorrhages which are not symptomatic, are classified as asymptomatic.
Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)
including information of the seriousness, treatment needed, resolution and relevant judgment concerning the causal relationship with the investigational device, SmartCT R3, comparator (CT/MR), or procedure will be summarized for safety information.
Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)
including information of the seriousness, treatment needed, resolution and relevant judgment concerning the causal relationship with the investigational devices, released SmartCT R3 product or procedure will be summarized for safety information.
Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)
including any corrective actions taken during the study, if any, will be summarized for safety information.
Time frame: Peri-procedural time
Door-to-randomization time: Time patient arrives at the Comprehensive Stroke Center door to the time of randomization
Time frame: Peri-procedural time
Door-to-imaging time: Time patient arrives at the Comprehensive Stroke Center door to the time of initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR)
Time frame: Peri-procedural time
Randomization-to-imaging time: Time of randomization to the time of initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR)
Time frame: Peri-procedural time
Randomization-to-puncture time: Time of randomization to the time the skin of the patient is touched to perform first arterial puncture
Time frame: Peri-procedural time
Door-to-thrombolytics administration time: Time patient arrives at the CSC door to the time of start of thrombolytics administration.
Time frame: Peri-procedural time
Onset-to-door time: Time patient last seen well to the time the patient arrives at the Comprehensive Stroke Center door
Time frame: Peri-procedural time
Onset-to-arterial puncture time: Time patient last seen well to the time the skin of the patient is touched to perform first arterial puncture
Time frame: Peri-procedural time
Onset-to-successful reperfusion (eTICI ≥ 2b) time: Time patient last seen well to the time of successful vessel recanalization (based on angiogram).
Time frame: Peri-procedural time
Emergency Medical Services call-to-door time: Time from the call to Emergency Medical Services to the time the patient arrives at the Comprehensive Stroke Center door (total ambulance service time)
Time frame: Peri-procedural time
Comprehensive Stroke Center notification call-to-door time: Time from notification call to the Comprehensive Stroke Center stroke team to the time the patient arrives at the Comprehensive Stroke Center door
Time frame: Peri-procedural time
Imaging-to-thrombolytics administration time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to the time of start of thrombolytics administration.
Time frame: Peri-procedural time
Imaging-to-arterial puncture time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to the time the skin of the patient is touched to perform first arterial puncture
Time frame: Peri-procedural time
Door-to-device deployment (first pass) time: Time patient arrives at the CSC door to the time of device deployment (first pass).
Time frame: Peri-procedural time
Imaging-to-successful reperfusion (eTICI ≥ 2b) time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to time of successful vessel recanalization (based on angiogram).
Time frame: Peri-procedural time
Arterial puncture-to-successful reperfusion (eTICI ≥ 2b) time: Time the skin of the patient is touched to perform first arterial puncture to the time of successful vessel recanalization.
Time frame: Peri-procedural time
Arterial puncture-to-end-of-EVT procedure (catheter out) time: Time the skin of the patient is touched to perform first arterial puncture to the time of the catheter is taken out (total EVT procedure time)
Time frame: At discharge or 5-7 days post-procedure, and at 90 ± 14 days post-procedure
Defined as modified Rankin Scale score (scores 0-6) distribution at discharge or at 5-7 days post-procedure, whichever comes first, and at 90 ± 14 days.
Time frame: At admission (baseline), 24(-12/+24) hours after randomization, discharge or at 5-7 days post-procedure, whichever comes; and at 90 ± 14 days post-procedure
The National Institutes of Health Stroke Scale is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0
Time frame: At 90 ± 14 days post-procedure
Functional independence defined as mRS ≤ 2 at 90 days. The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: At 90 ± 14 days post-procedure
Utility-Weighted modified Ranking Scale. The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: At 90 ± 14 days post-procedure
Dichotomized mRS score (0-3 versus 4-6). The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: At 24 (-12/+24) hours post-procedure
Infarct volume evaluated on CT or MRI
Time frame: At 24 (-12/+24) hours after randomization
Defined as an NIHSS score of 0-2 or NIHSS improvement ≥ 8 points. The National Institutes of Health Stroke Scale is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0
Time frame: At the end of the endovascular procedure
Defined as expanded Thrombolysis in Cerebral Infarction) (eTICI) grade 2b, 2c or 3 on the post-procedure angiogram
Time frame: On day 1
Total X-ray Radiation Exposure measured as effective dose (mSv).
Contact information is provided by the study sponsor or research team.
Eshuis
CONTACT
Gerrits
CONTACT
Philips Clinical & Medical Affairs Global
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05378035
Arrhythmias, Cardiac, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT06469801
Acute Brain Injury, Brain Diseases
Kansas City, Missouri, United States
View Trial DetailsNCT07379190
Brain Diseases, Brain Infarction
Weifang, China/Shandong Province, China
View Trial DetailsNCT07253870
Brain Diseases, Cardiovascular Diseases
Lahore, Punjab Province, Pakistan
View Trial Details